Key result
Nano drug delivery systems provide a promising strategy for the treatment of atrial fibrillation by improving drug stability, enabling targeted delivery, and enhancing ablation effects.
Why the study?
Traditional drug therapy and ablation for AF have unsatisfactory success rates, high recurrence rates, and complication risks, while surgical treatment is highly traumatic.
Nano drug delivery systems provide a promising novel strategy for the treatment of atrial fibrillation by enhancing drug stability, bioavailability, and targeted delivery.
Should not yet change AF practice; leaves open targeted nano-drug delivery as a hypothesis-generating approach.
Atrial fibrillation (AF) is one of the most common sustained tachyarrhythmias worldwide, and its prevalence is positively correlated with aging. AF not only significantly reduces the quality of life of patients but also causes a series of complications, such as thromboembolism, stroke, and heart failure, increases the average number of hospitalizations of patients, and places a huge economic burden on patients and society. Traditional drug therapy and ablation have unsatisfactory success rates, high recurrence rates, and the risk of serious complications. Surgical treatment is highly traumatic. The nano drug delivery system has unique physical and chemical properties, and in the application of AF treatment, whether it is used to assist in enhancing the ablation effect or for targeted therapy, it provides a safer, more effective and more economical treatment strategy.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2022) conducted a review in Atrial fibrillation. Nano drug delivery systems was evaluated. Nano drug delivery systems provide a promising strategy for the treatment of atrial fibrillation by improving drug stability, enabling targeted delivery, and enhancing ablation effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: